Abstract: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to ?3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ?6-docosapentaenoic acid or ?3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 4 (i.e., “?4-desaturase”). In particular, ?4-desaturase may be utilized, for example, in the conversion of adrenic acid to ?6-docosapentaenoic acid and in the conversion of ?3-docosapentaenoic acid to docosahexaenoic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 4 (i.e., “?4-desaturase”). In particular, ?4-desaturase may be utilized, for example, in the conversion of adrenic acid to ?6-docosapentaenoic acid and in the conversion of ?3-docosapentaenoic acid to docosahexaenoic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 4 (i.e., “?4-desaturase”). In particular, ?4-desaturase may be utilized, for example, in the conversion of adrenic acid to ?6-docosapentaenoic acid and in the conversion of ?3-docosapentaenoic acid to docosahexaenoic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: This invention relates to compositions and methods for nutritional management of hepatic (liver) failure. In particular the invention is directed to a nutritionally complete formulation suitable for use as a supplement or total enteral feeding. The composition is specifically tailored to meet the requirements of hepatic patients in need of nutritional support. The composition comprises an organoleptically acceptable protein system designed to meet the altered metabolic needs of patients suffering from hepatic failure. The invention also relates to administering a nutritional composition comprising effective amounts of the branched-chain amino acids, valine, leucine, isoleucine, or mixtures thereof, and with or without a reduced amount of tyrosine, phenylalanine and tryptophan.

Abstract: An apparatus of monitoring motor vehicle's electric power and method thereof are provided. The apparatus is disposed in the motor vehicle and includes a monitor and alarm device parallel connected to both a battery to be measured and a starting motor of the motor vehicle. The starting motor is taken as a load for forming an outer loop sampling circuit, 1/t second is set as a sampling time interval during discharging, voltage and current curves are formed by connecting a plurality of continuous voltage values each sampled in 1/t second, a minimum voltage of the voltage curve is compared with a predetermined alarm value for determining a status of the battery to be measured, and an alarm is issued in time if the status of the battery to be measured is abnormal.

Abstract: A latch system used for providing a negative resistance. It includes a current source module used for providing at least one DC current. The latch system also includes a first cross-coupling module, which contains a first inverter, a second inverter, and an action module. The action module contains at least one action block, each of which contains a first device and a second device. The action module is electrically connected to the first and second inverter and is used for increasing the negative resistance of the latch system.

Abstract: Products, including nutritional products, dietary supplements and formulas, that contain long chain polyunsaturated fatty acids (LCPs or LC-PUFAs), specifically n-3 LCPs like DHA. Also a methods of using such products to control appetite and help treat and/or prevent obesity and conditions of overweight, especially in a pediatric population. Dietary DHA can act centrally as an antagonist of the CB1 receptor in the brain in opposition to the endocannabinoids that increase food intake. This is particularly advantageous when DHA is fed during periods of rapid brain growth such as infancy, childhood and adolescence.

Abstract: An apparatus of monitoring motor vehicle's electric power and method thereof are provided. The apparatus is disposed in the motor vehicle and includes a monitor and alarm device parallel connected to both a battery to be measured and a starting motor of the motor vehicle. The starting motor is taken as a load for forming an outer loop sampling circuit, 1/t second is set as a sampling time interval during discharging, voltage and current curves are formed by connecting a plurality of continuous voltage values each sampled in 1/t second, a minimum voltage of the voltage curve is compared with a predetermined alarm value for determining a status of the battery to be measured, and an alarm is issued in time if the status of the battery to be measured is abnormal.

Abstract: A method and a device for monitoring a motor vehicle's electric power, in which the method comprises the steps of sampling, calculating, comparing, displaying results, and counting intervals, and the device comprises a stabilizing circuit, a CPU, a voltage sampling circuit, a current control circuit, and a color lamp display circuit. The step of sampling is performed when the load and power transistor are enabled (i.e., there is a great amount of current) and with a very short sampling time so that the invention can inform a driver about a status of a battery by consuming very little power.

Abstract: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to &ohgr;3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, &ohgr;6-docosapentaenoic acid or &ohgr;3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “&Dgr;5-desaturase”) and at carbon 6 (i.e., “&Dgr;6-desaturase”) and to uses thereof. In particular, &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &ggr;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: Disclosed are isolated polynucleotides encoding an omega-3 desaturase and a delta-12 desaturase, the enzymes encoded by the isolated polynucleotides, vectors containing the isolated polynucleotides, transgenic hosts that contain the isolated polynucleotides that express the enzymes encoded thereby, methods for producing the desaturase enzymes, and method of using the enzymes to make polyunsaturated fatty acids. The isolated polynucleotides are derived from a fungus, Saprolegnia diclina (ATCC 56851). In particular, omega-3-desaturase may be utilized, for example, in the conversion of arachidonic acid (AA) to eicosapentaenoic acid (EPA). Delta-12 desaturase may be used, for example, in the conversion of oleic acid (OA) to linoleic (LA). EPA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “&Dgr;5-desaturase”) and at carbon 6 (i.e., “&Dgr;6-desaturase”) and to uses thereof. In particular, &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr; -linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &ggr;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, &ohgr;6-docosapentaenoic acid or &ohgr;3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “&Dgr;5-desaturase”) and at carbon 6 (i.e., “&Dgr;6-desaturase”) and to uses thereof. In particular, &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &ggr;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to &ohgr;3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, &ohgr;6-docosapentaenoic acid or &ohgr;3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The invention generally relates to synthesis of essential fatty acids and their derivatives, long-chain polyunsaturated fatty acids (LC-PUFAs) and eicosanoids in transfected cells and in transgenic animals.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “&Dgr;5-desaturase”) and at carbon 6 (i.e., “&Dgr;6-desaturase”) and to uses thereof. In particular, &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &ggr;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 4 (i.e., “&Dgr;4-desaturase”). In particular, &Dgr;4-desaturase may be utilized, for example, in the conversion of adrenic acid to &ohgr;6-docosapentaenoic acid and in the conversion of &ohgr;3-docosapentaenoic acid to docosahexaenoic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.